No Data
No Data
Obesity Drug Developer Metsera Files for $100M IPO
Dividend Aristocrats Can't Handle Rising Rates. These Are Better Income Bets. -- Barrons.com
Goldman Sachs Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Announces Target Price $124
The world's first oral GLP-1 receptor agonist, Novo-Nordisk A/S, has been fully launched in China.
On January 11, Gelonghui reported that Novo-Nordisk A/S announced the comprehensive launch of its Innovative Drug, Ozempic (semaglutide tablets), in China today. As the first oral GLP-1RA, Ozempic combines SNAC technology to achieve significant benefits such as lowering blood sugar, weight loss, blood pressure reduction, and lipid regulation. The once-daily oral administration will improve patient adherence, creating a new era in the treatment of type 2 diabetes, helping achieve quality blood sugar targets and comprehensive metabolic management, bringing new hope to 0.14 billion diabetes patients in China.
Express News | Novo-Nordisk A/S is confident in the economic prospects of China and its development in the country, and is willing to continue investing in the Chinese market.
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading